CTG Pharma SRL
This article was originally published in Start Up
Executive Summary
CTG Pharma SRL's founders believe that the unique properties of hydrogen sulfide (H2S) hold the key to exciting new anti-inflammatory therapeutics. The Italian start-up plans to tag already-approved compounds with an H2S-releasing molecule. The strategy has several potential advantages: it would create novel chemical entities, it would reduce the risks of drug development, and it could be applied with a variety of drugs.